Journey Medical Corporation (NASDAQ: DERM) released its Q4 2025 earnings on March 25 2026. The company reported revenue of $16.08 million, falling short of the consensus estimate of $19.24 million (or $18.86 million). Non‑GAAP earnings per share were $‑0.04, beating the $‑0.06 estimate and narrowing the loss by $0.02.
The revenue shortfall was driven largely by timing issues with reimbursement and formulary implementation for its new oral rosacea therapy, EMROSI. Although EMROSI generated $14.7 million in net sales during the three quarters it was available, the company’s gross‑to‑net conversion was lower than expected in Q4, reflecting delayed payer coverage decisions.
The EPS beat can be attributed to disciplined cost management and a favorable product mix. The higher contribution from high‑margin products such as EMROSI and QBREXZA offset the lower revenue, allowing the company to narrow its loss despite the revenue miss.
Full‑year 2025 results show total revenue of $61.9 million, a 10% increase from $56.1 million in 2024. GAAP net loss was $11.4 million, or $0.47 per share, a reduction from the $14.7 million loss ($0.72 per share) reported in 2024. Adjusted EBITDA turned positive at $2.9 million, up from $800,000 in 2024, and gross margin expanded to 66.2% from 62.8%.
Management guided for continued growth in 2026, maintaining a positive adjusted EBITDA outlook and announcing plans to launch one or two additional dermatology products in the second half of the year. The company expects reimbursement rates to improve as coverage decisions mature.
CEO Claude Maraoui described 2025 as a “milestone year,” noting that the company achieved 11% net product revenue growth and a 3.5‑percentage‑point margin improvement. CFO Joseph Benesch highlighted the margin expansion and the positive EBITDA trajectory, emphasizing the impact of the favorable product mix.
Investor sentiment was negative following the release, largely driven by the revenue miss. The market’s reaction underscored the importance of meeting top‑line expectations for a commercial‑stage company, even as the company demonstrated progress in profitability and product mix.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.